FR2501507A1 - - Google Patents
Download PDFInfo
- Publication number
- FR2501507A1 FR2501507A1 FR8203942A FR8203942A FR2501507A1 FR 2501507 A1 FR2501507 A1 FR 2501507A1 FR 8203942 A FR8203942 A FR 8203942A FR 8203942 A FR8203942 A FR 8203942A FR 2501507 A1 FR2501507 A1 FR 2501507A1
- Authority
- FR
- France
- Prior art keywords
- insulin
- preparation
- calcium
- magnesium
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims abstract description 195
- 108090001061 Insulin Proteins 0.000 claims abstract description 96
- 102000004877 Insulin Human genes 0.000 claims abstract description 96
- 229940125396 insulin Drugs 0.000 claims abstract description 96
- 238000002360 preparation method Methods 0.000 claims abstract description 29
- 239000011575 calcium Substances 0.000 claims abstract description 28
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 26
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 18
- 239000011777 magnesium Substances 0.000 claims abstract description 13
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229910052749 magnesium Inorganic materials 0.000 claims abstract description 11
- 229910001424 calcium ion Inorganic materials 0.000 claims abstract description 9
- 238000001556 precipitation Methods 0.000 claims abstract description 9
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229910001425 magnesium ion Inorganic materials 0.000 claims abstract description 8
- 239000003755 preservative agent Substances 0.000 claims abstract description 7
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 6
- 150000001875 compounds Chemical class 0.000 claims abstract description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 8
- 230000003204 osmotic effect Effects 0.000 claims description 6
- 230000002335 preservative effect Effects 0.000 claims description 6
- 239000006174 pH buffer Substances 0.000 claims description 5
- LEMUFSYUPGXXCM-JNEQYSBXSA-N caninsulin Chemical compound [Zn].C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC3N=CN=C3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1C=NC=N1 LEMUFSYUPGXXCM-JNEQYSBXSA-N 0.000 claims description 4
- 230000001105 regulatory effect Effects 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 2
- 229910017604 nitric acid Inorganic materials 0.000 claims description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims 1
- 238000009877 rendering Methods 0.000 claims 1
- 239000000243 solution Substances 0.000 description 57
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 33
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- 229960005069 calcium Drugs 0.000 description 17
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 12
- 229960002713 calcium chloride Drugs 0.000 description 12
- 239000001110 calcium chloride Substances 0.000 description 12
- 229910001628 calcium chloride Inorganic materials 0.000 description 12
- 239000007864 aqueous solution Substances 0.000 description 11
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 9
- 238000001914 filtration Methods 0.000 description 9
- 229910052725 zinc Inorganic materials 0.000 description 9
- 239000011701 zinc Substances 0.000 description 9
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 8
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 239000002253 acid Substances 0.000 description 5
- 150000004683 dihydrates Chemical class 0.000 description 5
- 229940091250 magnesium supplement Drugs 0.000 description 5
- 239000007983 Tris buffer Substances 0.000 description 4
- 229960002337 magnesium chloride Drugs 0.000 description 4
- 229910001629 magnesium chloride Inorganic materials 0.000 description 4
- 159000000003 magnesium salts Chemical class 0.000 description 4
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 3
- 108010005991 Pork Regular Insulin Proteins 0.000 description 3
- LLSDKQJKOVVTOJ-UHFFFAOYSA-L calcium chloride dihydrate Chemical compound O.O.[Cl-].[Cl-].[Ca+2] LLSDKQJKOVVTOJ-UHFFFAOYSA-L 0.000 description 3
- 229940052299 calcium chloride dihydrate Drugs 0.000 description 3
- 206010061592 cardiac fibrillation Diseases 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000002600 fibrillogenic effect Effects 0.000 description 3
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000000536 complexating effect Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 150000004687 hexahydrates Chemical class 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 238000005086 pumping Methods 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101001011741 Bos taurus Insulin Proteins 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- IXIBAKNTJSCKJM-BUBXBXGNSA-N bovine insulin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 IXIBAKNTJSCKJM-BUBXBXGNSA-N 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229930003836 cresol Natural products 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229940050906 magnesium chloride hexahydrate Drugs 0.000 description 1
- DHRRIBDTHFBPNG-UHFFFAOYSA-L magnesium dichloride hexahydrate Chemical compound O.O.O.O.O.O.[Mg+2].[Cl-].[Cl-] DHRRIBDTHFBPNG-UHFFFAOYSA-L 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 108010066090 neutral insulin Proteins 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 230000010494 opalescence Effects 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Dental Preparations (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB8107423 | 1981-03-10 | ||
| DK414381 | 1981-09-18 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2501507A1 true FR2501507A1 (enExample) | 1982-09-17 |
| FR2501507B1 FR2501507B1 (enExample) | 1986-04-18 |
Family
ID=26067363
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR8203942A Expired FR2501507B1 (enExample) | 1981-03-10 | 1982-03-09 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US4472385A (enExample) |
| EP (1) | EP0060141B1 (enExample) |
| AT (1) | ATE23269T1 (enExample) |
| AU (1) | AU550068B2 (enExample) |
| CA (1) | CA1170990A (enExample) |
| CH (1) | CH652031A5 (enExample) |
| DE (1) | DE3274064D1 (enExample) |
| ES (1) | ES510245A0 (enExample) |
| FI (1) | FI78838C (enExample) |
| FR (1) | FR2501507B1 (enExample) |
| GB (1) | GB2094145B (enExample) |
| IE (1) | IE52904B1 (enExample) |
| IT (1) | IT1150639B (enExample) |
| NO (1) | NO157843C (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1985002544A1 (en) * | 1983-12-16 | 1985-06-20 | Thomas Takemi Aoki | Insulin delivery algorithm |
| PH23446A (en) * | 1986-10-20 | 1989-08-07 | Novo Industri As | Peptide preparations |
| ES2053723T3 (es) * | 1987-02-25 | 1994-08-01 | Novo Nordisk As | Nuevos derivados de insulina. |
| US4789660A (en) * | 1987-09-10 | 1988-12-06 | American Home Products Corporation | Insulin administration using methyl and propyl paraben |
| HU228094B1 (en) † | 1996-06-20 | 2012-10-29 | Novo Nordisk As | Insulin preparations containing nacl |
| AR012894A1 (es) * | 1997-06-13 | 2000-11-22 | Lilly Co Eli | Formulacion de insulina en solucion estable, su uso para preparar un medicamento y proceso para la preparacion de la misma. |
| DE69924232D1 (de) * | 1998-01-09 | 2005-04-21 | Novo Nordisk As | Stabilisierte insulin-zubereitungen |
| US20020156434A1 (en) * | 1998-03-13 | 2002-10-24 | Minimed Inc. | Stabilizing catheter for protein drug delivery |
| WO2003094956A1 (en) | 2002-05-07 | 2003-11-20 | Novo Nordisk A/S | Soluble formulations comprising monomeric insulin and acylated insulin |
| US20030226223A1 (en) | 2002-06-11 | 2003-12-11 | The Procter & Gamble Co. | High efficiency electric toothbrush |
| US7322066B2 (en) | 2003-07-16 | 2008-01-29 | Church & Dwight Co., Inc. | Electric toothbrushes having movable, intermittently movable, and fixed bristles |
| US20050050659A1 (en) | 2003-09-09 | 2005-03-10 | The Procter & Gamble Company | Electric toothbrush comprising an electrically powered element |
| US20050053895A1 (en) | 2003-09-09 | 2005-03-10 | The Procter & Gamble Company Attention: Chief Patent Counsel | Illuminated electric toothbrushes emitting high luminous intensity toothbrush |
| FR2896164B1 (fr) * | 2006-01-18 | 2008-07-04 | Flamel Technologies Sa | Formulation colloidale d'insuline longue action et sa preparation |
| FR2943538B1 (fr) * | 2009-03-27 | 2011-05-20 | Adocia | Formulation a action rapide d'insuline recombinante humaine |
| US9018190B2 (en) | 2009-03-27 | 2015-04-28 | Adocia | Functionalized oligosaccharides |
| US20130231281A1 (en) | 2011-11-02 | 2013-09-05 | Adocia | Rapid acting insulin formulation comprising an oligosaccharide |
| EP2919804B1 (fr) | 2012-11-13 | 2018-01-31 | Adocia | Formulation à action rapide d'insuline comprenant un composé anionique substitué |
| WO2015120457A1 (en) * | 2014-02-10 | 2015-08-13 | Biodel Inc. | Stabilized ultra-rapid-acting insulin formulations |
| US9795678B2 (en) | 2014-05-14 | 2017-10-24 | Adocia | Fast-acting insulin composition comprising a substituted anionic compound and a polyanionic compound |
| FR3020947B1 (fr) | 2014-05-14 | 2018-08-31 | Adocia | Composition aqueuse comprenant au moins une proteine et un agent solubilisant, sa preparation et ses utilisations |
| FR3043557B1 (fr) | 2015-11-16 | 2019-05-31 | Adocia | Composition a action rapide d'insuline comprenant un citrate substitue |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR892194A (fr) * | 1938-06-29 | 1944-03-30 | Ig Farbenindustrie Ag | Procédé de fabrication de préparations à base d'insuline |
| FR662M (enExample) * | 1959-06-16 | 1961-07-10 | ||
| US3102077A (en) * | 1953-08-19 | 1963-08-27 | Christensen Henry Marinus | Preparation of insulin containing 2.75 to 8 percent zinc content |
| US4196196A (en) * | 1978-06-19 | 1980-04-01 | Tiholiz Ivan C | Divalen/monovalent bipolar cation therapy for enhancement of tissue perfusion and reperfusion in disease states |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2474729A (en) * | 1945-01-03 | 1949-06-28 | Rhone Poulenc Sa | Insulin preparations |
-
1982
- 1982-03-04 AU AU81114/82A patent/AU550068B2/en not_active Ceased
- 1982-03-09 FI FI820808A patent/FI78838C/fi not_active IP Right Cessation
- 1982-03-09 CH CH1447/82A patent/CH652031A5/de not_active IP Right Cessation
- 1982-03-09 AT AT82301207T patent/ATE23269T1/de not_active IP Right Cessation
- 1982-03-09 EP EP82301207A patent/EP0060141B1/en not_active Expired
- 1982-03-09 GB GB8206899A patent/GB2094145B/en not_active Expired
- 1982-03-09 CA CA000397937A patent/CA1170990A/en not_active Expired
- 1982-03-09 IT IT8220038A patent/IT1150639B/it active
- 1982-03-09 NO NO820742A patent/NO157843C/no unknown
- 1982-03-09 DE DE8282301207T patent/DE3274064D1/de not_active Expired
- 1982-03-09 IE IE536/82A patent/IE52904B1/en not_active IP Right Cessation
- 1982-03-09 ES ES82510245A patent/ES510245A0/es active Granted
- 1982-03-09 FR FR8203942A patent/FR2501507B1/fr not_active Expired
- 1982-03-09 US US06/356,343 patent/US4472385A/en not_active Expired - Lifetime
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR892194A (fr) * | 1938-06-29 | 1944-03-30 | Ig Farbenindustrie Ag | Procédé de fabrication de préparations à base d'insuline |
| US3102077A (en) * | 1953-08-19 | 1963-08-27 | Christensen Henry Marinus | Preparation of insulin containing 2.75 to 8 percent zinc content |
| FR662M (enExample) * | 1959-06-16 | 1961-07-10 | ||
| US4196196A (en) * | 1978-06-19 | 1980-04-01 | Tiholiz Ivan C | Divalen/monovalent bipolar cation therapy for enhancement of tissue perfusion and reperfusion in disease states |
Non-Patent Citations (2)
| Title |
|---|
| CHEMICAL ABSTRACTS, vol. 89, no. 5, 31 juillet 1978, page 343, no. 39950x, Columbus Ohio (USA); * |
| CHEMICAL ABSTRACTS, vol. 91, no. 3, 16 juillet 1979, page 218, no. 15481k, Columbus Ohio (USA); * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP0060141A2 (en) | 1982-09-15 |
| FI820808L (fi) | 1982-09-11 |
| FI78838B (fi) | 1989-06-30 |
| NO820742L (no) | 1982-09-13 |
| GB2094145B (en) | 1984-12-05 |
| ES8302462A1 (es) | 1983-01-16 |
| CH652031A5 (de) | 1985-10-31 |
| NO157843C (no) | 1988-06-01 |
| CA1170990A (en) | 1984-07-17 |
| FI78838C (fi) | 1989-10-10 |
| GB2094145A (en) | 1982-09-15 |
| US4472385A (en) | 1984-09-18 |
| AU550068B2 (en) | 1986-02-27 |
| NO157843B (no) | 1988-02-22 |
| AU8111482A (en) | 1982-09-16 |
| FR2501507B1 (enExample) | 1986-04-18 |
| ES510245A0 (es) | 1983-01-16 |
| ATE23269T1 (de) | 1986-11-15 |
| DE3274064D1 (en) | 1986-12-11 |
| IE820536L (en) | 1982-09-10 |
| EP0060141A3 (en) | 1983-08-24 |
| IT8220038A0 (it) | 1982-03-09 |
| IT1150639B (it) | 1986-12-17 |
| EP0060141B1 (en) | 1986-11-05 |
| IE52904B1 (en) | 1988-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR2521009A1 (fr) | Solutions stabilisees d'insuline et procede pour la preparation de celles-ci | |
| US4472385A (en) | Stabilized insulin preparations and method for their production | |
| EP2838506B1 (en) | Magnesium compositions for modulating the pharmacokinetics and pharmacodynamics of insulin, and injection site pain | |
| AU609596B2 (en) | Aqueous dialysis and rinsing solution for intraperitoneal administration | |
| US20120178675A1 (en) | Compositions And Methods For Modulating The Pharmacokinetics and Pharmacodynamics of Insulin | |
| JPS63502274A (ja) | Ｌ↓−乳酸および／またはピルビン酸アニオンを用いた流体式治療法 | |
| FR2943538A1 (fr) | Formulation a action rapide d'insuline recombinante humaine | |
| US20130095146A1 (en) | Ciclesonide containing aqueous pharmaceutical composition | |
| US20130056678A1 (en) | Pharmaceutical compositions containing carboxylated starch | |
| JPS59152320A (ja) | 水性製剤 | |
| BE892413A (fr) | Preparation d'insuline stabilisee et procede pour leur fabrication | |
| CA1103160A (en) | Infusion solution for the treatment of hepatic encephalopathy and method of using them | |
| US6054462A (en) | Intranasal antimigraine compositions | |
| JPH1029937A (ja) | メフェナム酸水溶液製剤 | |
| KR20220066317A (ko) | 피하 주사가능 인슐린 제제 및 투여 방법 | |
| EP1318821B1 (en) | Fluid for haemofiltration | |
| JPH11222427A (ja) | リドカインまたはその塩の水溶液の安定化方法およびリドカインまたはその塩の水溶液 | |
| JP3643879B2 (ja) | 電解質輸液組成物 | |
| TAKEUCHI et al. | Changes in transmucosal potential difference and luminal pH in anesthetized rat stomach after exposure to ethanol | |
| DK149833B (da) | Fremgangsmaade til fremstilling af et oploest zinkinsulinpraeparat, derer fysisk stabilt | |
| JP4320795B2 (ja) | 栄養輸液剤 | |
| DK150813B (da) | Fremgangsmaade til fremstilling af stabiliserede insulinoploesninger | |
| CA1278242C (en) | Aqueous solution for the urodynamic investigation of the urinary bladder | |
| JPS59190917A (ja) | 補給用電解質溶液 | |
| JP2000219641A (ja) | 薬物の血液脳関門透過性向上方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ST | Notification of lapse |